Medicrea reported worldwide sales growth in the first quarter of 2019.
Five things to know:
1. Medicrea reported 10 percent worldwide sales growth and 15 percent sales growth in the U.S. over the first quarter last year.
2. Last year, the company discontinued two distribution activities of third-party products and services, which generated lower than normal gross margins and contributing to an overall 6 percent sales decrease. However, the company doesn't expect the activities to have an impact on the six-month sales.
3. Surgical volume with the patient-specific UNiD implant increased 68 percent in the first quarter compared to the same period last year. To date, surgeons have performed 3,500 procedures with the UNiD technology, 60 percent of which were in the U.S.
4. Nationwide, 40 new surgeons adopted the UNiD ASI technology in the past 12 months. The company has filed five patent families with 35 titles in the U.S., Europe, Australia and Japan.
5. Medicrea filed for FDA clearance of at Tulip type pedicle screw system, which it plans to commercially launch in the second quarter.